At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Prasugrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Multicenter Study of Prasugrel Compared to Placebo in Adult Patients With Sickle Cell Disease
In Brief
A Phase 2 clinical trial evaluating Prasugrel and Placebo for Sickle Cell Anemia. Completed, enrolled 62 participants across 14 sites.
Detailed Summary
The purpose of this trial is to assess the safety of Prasugrel in adult patients with sickle cell disease (SCD) by monitoring the rate and severity of hemorrhagic events requiring medical intervention compared to placebo for 30 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Anemia
CountriesUnited States
CollaboratorsDaiichi Sankyo
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedJul 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedJul 21, 2010
Enrollment StartJul 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.9 years ago
Interventions
Prasugreldrug
Administered orally, once daily for 30 days.
Placebodrug
Administered orally, once daily for 30 days.